Lee Ainslie’s Meridian Bioscience Inc VIVO Stock Holding History

Lee Ainslie’s Portfolio VIVO Stock Details VIVO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-21,039	Closed	-$393K	–	906
2020 Q4	$393K	Buy	+21,039	New	+$393K	0.01%	404

Other funds holding VIVO

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

EARNEST Partners Atlanta, Georgia $27.7B AUM 52.44% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

Lee Ainslie's VIVO Position: Q1 2021 in Review

Lee Ainslie sold out of Meridian Bioscience Inc (VIVO) in Q1 2021, closing a stake of 21,039 shares — an estimated $393K sold.

Lee Ainslie first reported a position in VIVO in Q4 2020 and held it in 1 quarter. The position peaked at $393K in Q4 2020. 215 funds tracked by Wall St. Rank hold VIVO as of Q1 2021.

Lee Ainslie reported no remaining Meridian Bioscience Inc position as of Q1 2021 after selling out during the quarter.
Lee Ainslie sold 21,039 Meridian Bioscience Inc shares in Q1 2021, an estimated $393K.
Lee Ainslie first reported a position in Meridian Bioscience Inc in Q4 2020 and held it in 1 quarter.
Lee Ainslie's Meridian Bioscience Inc position peaked at $393K in Q4 2020.
215 funds tracked by Wall St. Rank held Meridian Bioscience Inc as of Q1 2021.

Based on Maverick Capital's 13F filing for Q1 2021, filed 17 May 2021.